Support group for mums from different ethnicities
Carolyn Nansubuga, a Cheltenham mother-of-four, attended several groups following the birth of her youngest child, now 20 months, but said she struggled as she "never had anything in common with the other mums".
Lives of Colour, a Gloucestershire-based race equity charity, will launch the Mothers of Colour group at Aspire Foundation, Cheltenham on Thursday, in partnership with the NHS perinatal maternity unit.
Florence Nyasamo, charity founder, said the partnership will allow the health needs of mothers from all ethnicities to be met.
More news stories for Gloucestershire
Listen to the latest news for Gloucestershire
National audit programme "Mothers and Babies: Reducing Risk through Audits, External" (MBRRACE-UK) found maternal deaths among black women were nearly three times higher compared with those of white women in 2020-22.
The Mothers of Colour group will cover newborn care, mental wellness, and maternal health.
Ms Nansubuga said, at the sessions, she hopes to meet mothers who "understand the cultural nuances" she experiences after not "fitting in" previously.
"Groups are meant to give you rest from the mundane things of motherhood you've been going through at home so, when you go there, you have to feel welcome," she said.
"But it's not just me, even my baby would think 'I don't look like everybody else here'.
"When I heard about this group starting up I was super excited because, finally, we have the chance to attend a baby group and be ourselves."
Ms Nyasamo said it can be hard for women who have moved from another country to understand the "small nuances" at groups in the UK.
"It's nice to go into a space where you can just be," she said.
"We know with the NHS partnership, if we need a midwife or health visitor to come and have a conversation, then we've already got those connections.
"Whatever the women will ask for, we'll do our best to make sure their needs are met."
Mothers of Colour is open to women of all ethnicities.
Follow BBC Gloucestershire on Facebook, X and Instagram. Send your story ideas to us on email or via WhatsApp on 0800 313 4630.
Postnatal support group set up for black mothers
Letter scheme aims to give voice to black mums
Maternity care for black women must improve - MP
Lives of Colour
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
First new treatment for advanced bladder cancer in decades given green light
A new treatment for advanced bladder cancer which doubles survival time has been given the green light for NHS use. Experts said the approval of the new treatment combination would bring a 'fundamental shift' in care for patients with late-stage disease, saying that until now, the treatment for advanced bladder cancer had not significantly changed since the 1980s. They said there had been real 'unmet need' for patients with advanced disease, with some 29% of people diagnosed with stage 4 cancer – when the cancer has spread to other parts of the body – surviving for a year after diagnosis. It is estimated that 1,250 people a year could benefit from the treatment. The new treatment combination includes enfortumab vedotin, an antibody-drug which is also known as Padcev, made by Astellas and Pfizer – with pembrolizumab, a drug known as a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest that the treatment combination, when tested against platinum-based chemotherapy, led to improved survival for patients. 'Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since the 1980s,' Professor Thomas Powles, director of Barts Cancer Institute Biomedical Research Centre (QMUL), UK and primary investigator on the trial, said. 'This guidance will fundamentally reshape first-line treatment for eligible patients.' Trial data indicated that patients who took the treatment combination survived for an average of 33.8 months compared to 15.9 months with chemotherapy. Researchers also measured the amount of time people survived without their disease worsening – also known as progression-free survival – and found that people on the combination treatment had just more than a year of progression-free survival compared to half-a-year for those on standard treatment. Three in 10 (30%) patients had a so-called 'complete response' when getting the combination treatment – meaning there was no evidence of cancer remaining. This was compared to 14.5% of those who received chemotherapy. One patient said that taking part in the trial had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, received the combination treatment on a trial at Barts Health NHS Trust after surgery to remove his tumours failed. He said: 'I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. 'Immediately after the operation that failed, I asked the doctor what the prognosis was, and he said, most people in your position live for a year, and now, three-and-a-half years later here I am. 'I am going to have an extra few years to see my grandson grow up – and maybe even be around to see him get married.' The treatment combination will now be available for NHS patients in England following the approval from the National Institute for Health and Care Excellence (Nice) for patients with 'unresectable or metastatic urothelial cancer for people who are eligible for platinum-containing chemotherapy' and is given as an IV infusion in hospitals or clinics. Dr Timir Patel, medical director of Astellas UK, said: 'The guidance from Nice is excellent news for patients. 'Advanced bladder cancer is in an area where there is a real unmet need. 'This combination therapy changes the standard of care for doctors and their patients.' Helen Knight, director of medicines evaluation at Nice, said: 'This is a highly promising and effective new drug, with clinical trial results highlighting the tremendous difference it could make to the length and quality of people's lives. 'Advanced bladder cancer is a devastating condition which can have a substantial impact on people's daily lives, often leading to them struggling to work, travel or maintain physical activity.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a treatment that can almost double their chances of survival, helping thousands to live longer and giving them more precious moments with their loved ones. 'Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.' Jeannie Rigby, chief executive of charity Action Bladder Cancer UK, said: 'This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available.' Around 18,000 people in England are diagnosed with bladder cancer each year.
.jpeg&w=3840&q=100)
Miami Herald
an hour ago
- Miami Herald
Red panda known for ‘playful sass' dies, Utah zoo says. She was a guest favorite
An 8-year-old red panda known for her 'playful sass' and 'calm confidence' died after a severe health decline, Utah zookeepers said. Kiaria, a Chinese red panda, came to the Hogle Zoo in November as part of a breeding program by the Association of Zoos and Aquariums' Red Panda Species Survival Plan (SSP), according to an Aug. 18 news release by the Salt Lake City-based zoo. Kiaria had a history of gastrointestinal issues, which are common for red pandas, under human care, but in the recent months, she 'had been eating well, sleeping, and showing her playful personality,' the zoo said. On Aug. 14, her health began to rapidly decline, and after trying various treatments, the veterinary staff determined she would not recover, so she was humanely euthanized, zookeepers said. Gastrointestinal issues are the third-leading cause of death in Chinese red pandas living in North American zoos, SSP Red Panda co-vet advisor James Steeil said in the release. The 'confident' Kiaria, known as the 'boss of the cool room,' became a guest favorite after being debuted in March, the zoo said. She would spend time with William, a 2-year-old Chinese red panda, as part of the breeding program but preferred her own space as red pandas are 'naturally solitary,' the zoo said. Chinese red pandas have reddish coats and stripes on their tails with 'larger bodies and longer fur to help retain warmth,' zookeepers said. The species faces threats of habitat loss and poaching, causing a 40% decline in overall population of Chinese red pandasin the last 20 years, the zoo said. 'It was an immense privilege to have Kiaria in our care. She was a meaningful ambassador for her endangered species, helping to inspire greater understanding and appreciation for red pandas,' zookeepers said.
Los Angeles Times
2 hours ago
- Los Angeles Times
New Report on State of Technology in Value-Based Care Exposes Tech and Data Barriers
Glendale-based Reveleer, a leading value-based care technology platform, in partnership with Mathematica, a policy data and analytics company, has released the '2025 State of Technology in Value-Based Care Report.' The report comes during a pivotal moment in healthcare transformation. While payer and provider alignment around value-based care (VBC) has never been stronger, execution is falling behind. The report reveals that while there is widespread confidence in technology's potential to support value-based care, significant barriers such as fragmented data strategies, uneven AI adoption and insufficient staff training are hindering progress and scalability. The report findings defy a common industry narrative that payers and providers are misaligned on priorities. In fact, 100% of providers and 97% of payers surveyed agree their value-based care goals are strongly aligned. What's missing is synchronized execution. Despite shared vision, payers and providers are operating in parallel rather than in concert, pointing to an inefficiency that limits the impact of technology investments and makes scale more difficult. Meanwhile, momentum continues to build: 92% of payers and 81% of providers surveyed saw their VBC contracts grow in the past 12 months. And even more expect growth ahead, with 94% of payers and 83% of providers forecasting increases in the next 12 months. But if execution continues to lag behind ambition, progress may stall before it can transform care. 'To realize the full potential of value-based care, payers and providers must collaborate at scale,' said Jay Ackerman, CEO of Reveleer. 'The good news is payers and providers are finally rowing in the same direction. But if they don't row in sync, we won't move forward. This report points to a clear call to action. The alignment is there, and the tools are ready. Tighter collaboration and true transformation are within reach.' Data management is viewed as a strategic asset by virtually every organization surveyed. 97% of providers and 96% of payers agree that a strong data management approach gives them a competitive edge in the marketplace. Yet behind that confidence lies significant operational fragmentation. Only a third of surveyed providers (33%) and payers (31%) rate their data integration capabilities as 'excellent.' Yet only about half (46% of providers and 53% of payers) are very confident in the accuracy and completeness of the patient data they use in VBC initiatives. This gap between perception and precision signals a major vulnerability in scaling VBC effectively and safely. Every payer and provider surveyed reports using AI. And most agree it's delivering results: 96% of both payers and providers agree their approach to AI adoption and implementation has given them a competitive advantage, and more than 80% of each report seeing positive impacts, including: But enthusiasm hasn't translated into full commitment. Only 40% of payers and 38% of providers say they are fully committed to AI adoption. Just 21% of payers and 29% of providers report a significant increase in AI use in the past 12 months. Underlying this hesitation are concerns about AI hallucinations, algorithmic transparency and the ethics of AI-assisted decisions without human oversight. These concerns don't negate AI's value, but they do signal the need for more robust frameworks for responsible adoption. Despite confidence in AI's promise, organizations are underinvesting in the people who need to use it. While all organizations surveyed offer at least some AI training, only 30% of payers and 32% of provider organizations offer extensive training programs. This lack of preparation is a likely contributor to AI hesitancy and a barrier to scaling its use. As the pressure to improve outcomes and reduce costs intensifies, organizations that pair technology with workforce readiness will be better positioned to lead. 'Technology is a powerful enabler, but it's not a magic wand,' said Ngan MacDonald, director of data innovations at Mathematica. 'The path to scalable value-based care demands more than alignment. It demands real investment in data infrastructure, workforce readiness and AI governance. This report highlights where the friction lies and where leaders need to focus next.' Information sourced from Reveleer. To learn more, contact srubin@
